Ascendiant Capital Markets Issues Positive Forecast for Lucid Diagnostics (NASDAQ:LUCD) Stock Price

Lucid Diagnostics (NASDAQ:LUCD) had its price objective hoisted by Ascendiant Capital Markets from $7.75 to $8.00 in a research report report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other analysts have also recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Saturday, September 27th. Needham & Company LLC reissued a “buy” rating and set a $3.00 price target on shares of Lucid Diagnostics in a report on Wednesday, August 13th. BTIG Research raised their price objective on shares of Lucid Diagnostics from $2.00 to $2.50 and gave the company a “buy” rating in a research report on Friday, September 5th. Finally, Wall Street Zen cut Lucid Diagnostics from a “hold” rating to a “sell” rating in a research report on Monday. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $3.70.

Lucid Diagnostics Price Performance

Shares of NASDAQ LUCD opened at $1.03 on Monday. The stock has a fifty day moving average price of $1.08 and a 200 day moving average price of $1.21. Lucid Diagnostics has a 1-year low of $0.75 and a 1-year high of $1.80. The company has a market cap of $137.48 million, a PE ratio of -0.87 and a beta of 1.19.

Insiders Place Their Bets

In other Lucid Diagnostics news, Director Dennis Matheis bought 100,000 shares of the company’s stock in a transaction on Wednesday, August 20th. The stock was purchased at an average cost of $1.02 per share, for a total transaction of $102,000.00. Following the acquisition, the director owned 665,443 shares of the company’s stock, valued at $678,751.86. The trade was a 17.69% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 6.80% of the company’s stock.

Institutional Trading of Lucid Diagnostics

Large investors have recently modified their holdings of the business. Alyeska Investment Group L.P. acquired a new position in shares of Lucid Diagnostics during the 1st quarter worth approximately $2,813,000. Geode Capital Management LLC increased its position in Lucid Diagnostics by 420.3% during the second quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock worth $1,814,000 after buying an additional 1,274,194 shares in the last quarter. Ghisallo Capital Management LLC acquired a new position in shares of Lucid Diagnostics in the first quarter worth $629,000. XML Financial LLC purchased a new stake in shares of Lucid Diagnostics in the first quarter valued at $266,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Lucid Diagnostics in the fourth quarter valued at $98,000. 74.01% of the stock is currently owned by institutional investors and hedge funds.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.